IQWiG

Drug assessment at a glance: A26-09[1]

Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years)

24 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-09. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Paediatric patients aged 1 to < 3 years with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1
Intervention	selumetinib
Comparator	Best supportive care
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available. A single-arm study of selumetinib in children aged ≥ 1 to < 7 years, which did not allow a comparison versus the appropriate comparator therapy, was presented in the dossier. Two studies of selumetinib in patients from older age groups were additionally presented. However, it was not possible to transfer evidence from older age groups to the target population under assessment, partly because there was uncertainty as to whether the course of disease is sufficiently comparable across the age groups.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Selumetinib (plexiforme Neurofibrome bei Neurofibromatose Typ 1, 1 bis < 3 Jahre); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 19.08.2026]. URL: https://doi.org/10.60584/A26-09.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Selumetinib (plexiforme Neurofibrome bei Neurofibromatose Typ 1, 1 bis < 3 Jahre); Addendum zum Projekt A26-09 (Dossierbewertung) [online]. 2026 [Accessed: 19.08.2026]. URL: https://doi.org/10.60584/A26-76.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Selumetinib (Neues Anwendungsgebiet: Neurofibromatose Typ 1 (≥ 1 bis < 3 Jahre)) [online]. 2026 [Accessed: 19.08.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1311/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-09.html and https://www.iqwig.de/en/projects/a26-76.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de